Skip to content

EV / EBITDA at other companies

Eli Lilly logo
Eli LillyLLY
25.9×-24.4×
AbbVie logo
AbbVieABBV
19.8×
Bausch Health Companies logo
Bausch Health CompaniesBHC
12×+3.9×

Other financials

Income statement

See full
Revenue$39.4M0.0%
Gross profit$23.8M+1.6%
Operating income-$1.8M-13.4%
Net income-$2.4M+15.8%
EPS (diluted)-$0.03+40.0%

Balance sheet

See full
Cash & equivalents$16.7M+201%
Total debt$71.0M-27.1%
Total equity$100.3M+31.5%
Total assets$192.0M-5.5%

Cash flow

See full
Operating cash flow$5.3M+507%
CapEx$51.0K-97.3%
Free cash flow$5.2M+605%

Valuation

See full
Market cap$311.81M+4.7%
Enterprise value$366.14M-6.0%
P/S2.1×+0.3×

Profitability

See full
Gross margin59.6%-0.3pp
Operating margin-7.8%-0.4pp
Net margin-11.3%-25.1pp
FCF margin-0.1%

Returns & leverage

See full
Return on equity-21.6%-78.3pp
Debt / equity0.7×-0.6×
Current ratio0.7×+0.2×

Where this comes from

Calculated from AirSculpt Technologies, Inc.’s reported figures.

Based on the most recent quarter.

The official record: AirSculpt Technologies, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about AirSculpt Technologies, Inc.'s ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AirSculpt Technologies, Inc.'s EV / EBITDA?
AirSculpt Technologies, Inc. (AIRS) reported EV / EBITDA of 293.5× in Q1 2026.
What is the long-term trend for AirSculpt Technologies, Inc.'s EV / EBITDA?
Over 3 years (2022 to 2025), AirSculpt Technologies, Inc.'s EV / EBITDA has grown at a 23.2% compound annual growth rate (CAGR), from 87× to 162.8×.
What does EV / EBITDA mean?
Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.